Compare Stocks → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:DYNNASDAQ:JANXNASDAQ:PNTNASDAQ:YMAB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.24-1.6%$1.21$0.59▼$11.12$87.95M0.211.75 million shs598,346 shsDYNDyne Therapeutics$28.39-0.4%$24.01$6.40▼$30.27$2.34B0.951.91 million shs1.32 million shsJANXJanux Therapeutics$37.65-0.7%$24.28$5.65▼$58.69$1.96B4.31802,335 shs395,976 shsPNTPOINT Biopharma Global$12.50+0.2%$12.98$6.57▼$14.35$1.33BN/A1.44 million shs3.29 million shsYMABY-mAbs Therapeutics$16.26-1.5%$14.85$3.13▼$20.90$722.32M0.75364,047 shs270,332 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-1.59%+3.33%+3.33%+18.10%-84.97%DYNDyne Therapeutics-0.39%-2.71%+15.41%+113.46%+154.62%JANXJanux Therapeutics-0.71%-5.52%-24.32%+250.89%+200.00%PNTPOINT Biopharma Global0.00%0.00%0.00%0.00%+73.13%YMABY-mAbs Therapeutics-1.45%-4.01%-1.45%+138.42%+401.85%“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.9445 of 5 stars3.14.00.00.03.21.71.3DYNDyne Therapeutics4.0176 of 5 stars4.62.00.00.02.55.00.6JANXJanux Therapeutics3.1162 of 5 stars4.51.00.00.03.23.30.0PNTPOINT Biopharma Global0.1744 of 5 stars1.00.00.00.00.01.71.9YMABY-mAbs Therapeutics0.7694 of 5 stars1.12.00.00.02.84.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,694.35% UpsideDYNDyne Therapeutics3.14Buy$37.4331.84% UpsideJANXJanux Therapeutics3.00Buy$59.6058.30% UpsidePNTPOINT Biopharma Global2.00Hold$12.802.40% UpsideYMABY-mAbs Therapeutics2.29Hold$16.571.92% UpsideCurrent Analyst RatingsLatest YMAB, PNT, DYN, JANX, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/21/2024JANXJanux TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.003/20/2024JANXJanux TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$100.003/13/2024JANXJanux TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $48.003/11/2024JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$53.003/8/2024DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $31.003/6/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.003/6/2024DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $41.003/6/2024DYNDyne TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $29.003/6/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.003/5/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$44.00 ➝ $47.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.81N/AN/A$2.22 per share0.56DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AJANXJanux Therapeutics$8.08M240.72N/AN/A$7.46 per share5.05PNTPOINT Biopharma Global$226.58M5.88$0.94 per share13.31$4.68 per share2.67YMABY-mAbs Therapeutics$84.82M8.39N/AN/A$2.32 per share7.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)DYNDyne Therapeutics-$235.94M-$3.94N/AN/AN/AN/A-136.35%-103.67%5/9/2024 (Estimated)JANXJanux Therapeutics-$58.29M-$1.34N/AN/AN/A-721.18%-17.88%-15.95%5/14/2024 (Estimated)PNTPOINT Biopharma Global$98.29M$0.9013.89N/AN/A39.62%21.10%18.28%N/AYMABY-mAbs Therapeutics-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)Latest YMAB, PNT, DYN, JANX, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/202412/31/2023DYNDyne Therapeutics-$0.92-$1.09-$0.17-$1.09N/AN/A2/29/2024Q4 2023YMABY-mAbs Therapeutics-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 million2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/APNTPOINT Biopharma GlobalN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16DYNDyne TherapeuticsN/A2.532.53JANXJanux TherapeuticsN/A26.8026.80PNTPOINT Biopharma Global0.019.149.14YMABY-mAbs TherapeuticsN/A5.525.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%DYNDyne Therapeutics96.68%JANXJanux Therapeutics75.39%PNTPOINT Biopharma Global59.53%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%DYNDyne Therapeutics32.89%JANXJanux Therapeutics35.40%PNTPOINT Biopharma Global16.00%YMABY-mAbs Therapeutics21.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableDYNDyne Therapeutics14181.96 million55.00 millionOptionableJANXJanux Therapeutics6451.66 million33.37 millionOptionablePNTPOINT Biopharma Global129106.57 million89.52 millionOptionableYMABY-mAbs Therapeutics10043.78 million34.37 millionOptionableYMAB, PNT, DYN, JANX, and ACRS HeadlinesSourceHeadlineWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Betzacks.com - March 28 at 10:56 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%marketbeat.com - March 26 at 12:38 PMYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?zacks.com - March 20 at 8:40 AMY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3%marketbeat.com - March 19 at 11:57 AMY-mAbs Therapeutics Finance Chief Bo Kruse Resignsmarketwatch.com - March 15 at 8:31 AMY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officerfinanznachrichten.de - March 14 at 2:58 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84marketbeat.com - March 14 at 11:56 AMY-mAbs Therapeutics CFO Bo Kruse To Retiremarkets.businessinsider.com - March 14 at 9:57 AMY-mAbs Therapeutics Announces Resignation of Chief Financial Officerglobenewswire.com - March 14 at 9:05 AMGSA Capital Partners LLP Acquires 92,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)marketbeat.com - March 13 at 5:32 AMWall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?zacks.com - March 12 at 10:55 AMBAMF, Corewell Health partner on clinical trial for advanced cancer treatmentcrainsgrandrapids.com - March 11 at 3:17 PMY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.3%marketbeat.com - March 11 at 11:52 AMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LPmarketbeat.com - March 11 at 5:14 AMCracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeuticsmarkets.businessinsider.com - March 6 at 6:21 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 8.2% Following Analyst Upgrademarketbeat.com - March 6 at 11:45 AMHC Wainwright Raises Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $22.00marketbeat.com - March 6 at 8:25 AMAre You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choicezacks.com - March 5 at 1:01 PMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 4 at 1:15 PMY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Raised to $26.00 at Canaccord Genuity Groupmarketbeat.com - March 4 at 10:25 AMY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directorsglobenewswire.com - March 4 at 7:30 AMY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directorsglobenewswire.com - March 4 at 7:30 AMY-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 3 at 2:52 PMQ4 2023 Y-mAbs Therapeutics Inc Earnings Callfinance.yahoo.com - March 2 at 1:35 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?5 Ways Ralph Lauren Stock is Dressed for SuccessMarch 1, 2024 9:35 AMView 5 Ways Ralph Lauren Stock is Dressed for SuccessAll Headlines Company DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Dyne TherapeuticsNASDAQ:DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Janux TherapeuticsNASDAQ:JANXJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.POINT Biopharma GlobalNASDAQ:PNTPOINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Y-mAbs TherapeuticsNASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.